<DOC>
	<DOCNO>NCT02588105</DOCNO>
	<brief_summary>The purpose study determine whether AZD0156 safe , best dose give , process body give alone combination agent . The study also collect initial information effective .</brief_summary>
	<brief_title>Study Assess Safety Preliminary Efficacy AZD0156 Increasing Doses Alone Combination With Other Anti-cancer Treatment Patients With Advanced Cancer</brief_title>
	<detailed_description>The study consist number study module , evaluate safety tolerability AZD0156 specific combination agent . The combination option may require initial monotherapy dose escalation gain understanding pharmacokinetics , safety tolerability initiate dose escalation combination . An oral formulation AZD0156 use . Module 1 explores AZD0156 combination olaparib Additional module may add explore AZD0156 monotherapy combination agent may different tumour type . An expansion cohort module 1 may enroll additional patient include , limited , patient advance gastric adenocarcinoma , explore safety , tolerability , pharmacokinetics biological activity select dose ( ) alternate dose schedule , get preliminary assessment efficacy . During dose expansion phase study module , preliminary investigation effect food exposure may make .</detailed_description>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>Inclusion criterion part study Confirmation locally advanced/metastatic cancer . Refractory resistant standard therapy , effective standard Aged least 18 yr Reasonable health ( performance status 0 1 ) , stable previous 2 week Females child must use contraception ; negative pregnancy test , &amp; breast feeding Sexually active male patient must use contraception duration study 3 month afterwards Inclusion criterion Part B Tumour ( ) measure CT MRI , least 1cm size Inclusion Module 1 ; olaparib specific part B Confirmation metastatic/locally advance cancer type fail respond standard treatment Exclusion criterion part study Prior treatment ATM inhibitor Past medical history inflammatory type ( interstitial ) lung disease current inflammatory lung disease Radiotherapy within last 4 week , except palliative radiotherapy bone pain relief Prior treatment drug may cause lung damage Poor lung function History/presence muscle weakness abnormal blood test relate muscle function Cancer affect spinal cord and/or brain unless asymptomatic stable Any evidence severe uncontrolled disease , active bleeding , kidney transplant , active infection include liver infection ( hepatitis B , hepatitis C ) human immunodeficiency virus ( HIV ) . Evidence severe lung infection Receiving , receive four week prior start study treatment chemotherapy treatment cancer Treatment certain dos steroid two week prior start study treatment A known sensitivity AZD0156 component Treatment unapproved medicine within 28 day prior start study treatment Receiving , receive medication , herbal supplement and/or food significantly affect liver works Low number certain blood cell If liver kidney n't work normally If heart n't work normally strong family history certain heart diseases Other cancer within past 3 year , except certain type cervical skin cancer Sickness vomiting , digestive disease previous significant bowel removal Patients uncontrolled fitting Infections require treatment Other severe and/or uncontrolled medical condition addition cancer Exclusion Module 1 ; olaparib specific part B A blockage digestive system severe bleed stomach within 4 week take medication stuy Patients acute leukaemia certain bone marrow diseases Patients know sensitivity olaparib component Any previous treatment drug work like olaparib .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase I , open label study ; safety efficacy AZD0156 ; ATM inhibitor</keyword>
</DOC>